Related Experiment Videos
Case reports: efalizumab-associated lymphoproliferative disease
Satya Bommakanti1, Amol Patil, Camellia Eshoa
1Division of Neoplastic Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA. sbommaka@mcw.edu
Journal of Drugs in Dermatology : JDD
|August 3, 2007
Summary
Efalizumab, an immunosuppressant for psoriasis, may increase lymphoma risk. This case details Epstein Barr Virus-associated large B cell lymphoma in a patient treated with efalizumab.
Area of Science:
- Immunology
- Oncology
- Dermatology
Background:
- Efalizumab is an immunosuppressive biologic approved for moderate to severe psoriasis.
- There is a growing body of evidence suggesting a potential link between efalizumab use and the development of malignancies, including lymphoma.
Observation:
- This report describes the first documented case of Epstein Barr Virus-associated large B cell lymphoma.
- The patient developed this specific malignancy following treatment with efalizumab for psoriasis.
Findings:
- The case highlights a rare but serious adverse event associated with efalizumab therapy.
- Epstein Barr Virus (EBV) was identified as a factor in the development of the large B cell lymphoma.
Implications:
- As immunosuppressive agents like efalizumab are increasingly prescribed, clinicians must be vigilant for potential malignancy development.
- A high index of suspicion for various cancers is warranted in patients undergoing treatment with immunosuppressants.
- Further research into the oncogenic risks associated with efalizumab and similar immunomodulatory drugs is crucial.